Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002786 · ClinicalTrials.gov registry record · Phase 1

Biological Therapy in Treating Patients With Metastatic Melanoma

A Phase 1 study of Melanoma (Skin), sponsored by Fred Hutchinson Cancer Center.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT00002786 is a Phase 1 study of Melanoma (Skin) that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 20 participants, below the 136-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002786, a Phase 1 study of Melanoma (Skin), has completed, sponsored by Fred Hutchinson Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I/II trial to study the effectiveness of biological therapy in treating patients who have metastatic melanoma.

Conditions Studied

Interventions

  • BIOLOGICAL aldesleukin
  • BIOLOGICAL therapeutic tumor infiltrating lymphocytes

Study Locations (1)

Washington

  • Fred Hutchinson Cancer Research Center - Seattle

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 1995-10
Est. Completion 2006-03
Phase Phase 1

Sponsor

Fred Hutchinson Cancer Center

483 total trials

What the Registry Record Tells You About NCT00002786

The ClinicalTrials.gov registry entry for NCT00002786 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 136-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (85% lower). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Melanoma (Skin) appearing as the primary indexed condition, and to 2 interventions - of which aldesleukin is the first listed.

NCT00002786 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT00002786 about?

NCT00002786 is a clinical study titled "Biological Therapy in Treating Patients With Metastatic Melanoma". RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I/II trial to study the effectiveness of biological therapy in treating patients who have metastatic melanoma.

What is the current status of trial NCT00002786?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 1995-10. Estimated completion is 2006-03.

What conditions does trial NCT00002786 study?

This clinical trial studies the following conditions: Melanoma (Skin).

What interventions are being tested in trial NCT00002786?

The interventions under investigation include: aldesleukin (BIOLOGICAL), therapeutic tumor infiltrating lymphocytes (BIOLOGICAL).

Who is sponsoring clinical trial NCT00002786?

This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002786 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Melanoma (Skin)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.